BAMCO Inc
IMVT icon

BAMCO Inc’s Immunovant IMVT Stock Holding History

BAMCO Inc’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$855K – 327
2024
Q3 		$855K Sell
30,000
-25,000
-45% -$737K ﹤0.01% 305
2024
Q2 		$1.45M Sell
55,000
-5,000
-8% -$142K ﹤0.01% 297
2024
Q1 		$1.94M Buy
60,000
+1,000
+2% +$36.5K 0.01% 297
2023
Q4 		$2.49M Buy
+59,000
New +$2.17M 0.01% 284

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BAMCO Inc's IMVT Position: Q4 2024 in Review

BAMCO Inc sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 30,000 shares — an estimated $855K sold.

BAMCO Inc first reported a position in IMVT in Q4 2023 and held it in 4 quarters. The position peaked at $2.49M in Q4 2023. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • BAMCO Inc reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • BAMCO Inc sold 30,000 Immunovant shares in Q4 2024, an estimated $855K.
  • BAMCO Inc first reported a position in Immunovant in Q4 2023 and held it in 4 quarters.
  • BAMCO Inc's Immunovant position peaked at $2.49M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on BAMCO Inc's 13F filing for Q4 2024, filed 14 Feb 2025.